We're aware of a cyber security incident affecting the electronic prescriptions provider MediSecure. The eRX Script Exchange (eRX) and the National Prescription Delivery Service (NPDS) continue to operate as usual and have not been impacted. Find out more and read our statement here.

Prescribing drugs of dependence in general practice

Part A - Clinical Governance Framework - Chapter 4

Accountable prescribing

Download PDF

Last revised: 01 Nov 2019


Accountable prescribing has been defined as a commitment to evidence-based practice, the use of medicines with proven effectiveness and the avoidance of medicines when they do not help or cause harm.45 This is particularly relevant to prescription drug misuse.

Good prescribing practice involves careful and considered diagnosis, clear therapeutic goals, the use of non-drug therapies where suitable, prescribing appropriate types, formulations and amounts of medication, explaining the effects of medications and any risk of dependence, and implementing regular medication reviews.

GPs are required to be accountable prescribers of drugs of dependence and must prescribe within legislative frameworks, professional standards and approved clinical guidelines.

To minimise the harms associated with prescription drug misuse, GPs need to maintain vigilance in identifying substance misuse or dependence, assist patients in recognising misuse or dependence where it exists, set goals for recovery and assist patients to seek appropriate treatment. Clinical tools have been developed for these purposes.

GPs must prescribe within legislative frameworks and should comply with professional standards and approved clinical guidelines
Reference to the Standards
(Extrapolated from Criterion 5.3.1)


GPs must seek a permit or authority from the relevant state or territory health department when prescribing an S8 drug to a patient who is drug dependent

GPs should maintain or improve their skills in relevant areas such as chronic pain, mental health or drugs of dependence
Reference to the Standards
(Extrapolated from Criterion 3.2.1, Flagged indicator C)

GPs should use universal precautions* to guide their approach to patient who require drugs of dependence
*Universal precautions here refers to the 10 steps of universal precautions in pain medicine.

GPs should inform patients that drugs of dependence are to be prescribed from only one practice and preferably by one GP, and drugs should be dispensed from one pharmacy

GPs must maintain professional boundaries when prescribing drugs of dependence

GPs have the right to discontinue care of a patient who has behaved in a violent or threatening manner
Reference to the Standards
(Extrapolated from Criterion 2.1.1)

GPs should be prepared to use specialist support to manage problematic drug use in patients with more complex issues or if the clinical situation deteriorates
Reference to the Standards
(Extrapolated from Criteria 3.1.2, 3.1.3, 4.1.2, 5.3.1)

GPs must ensure that patient records are clear, up-to-date and contain sufficient information for another practitioner to take over care
Reference to the Standards
(Adapted from Criteria 1.7.1, 1.7.2,1.7.3)

Professional boundaries

The public and health professions have an expectation that the therapeutic context is safe for patients. It is the health practitioner’s responsibility to behave ethically at all times and maintain professional boundaries.

With decreasing formality in medicine, GPs are more likely to encourage the use of first names and to develop a relaxed, collaborative relationship with their patients. All GPs should be mindful of simultaneously maintaining clear professional and personal boundaries.

Boundaries represent the edge of appropriate behaviour and serve two important purposes: they structure the professional relationship in ways that maintain the identity and roles of the patient and the professional and they separate the therapeutic relationship from social, sexual, romantic and business relationships.

Setting professional boundaries may include:46

  • practitioner behaviour standards
  • using universal precautions
  • not prescribing or dispensing controlled substances for self or family.

Legal obligations

All practitioners have a duty to act within state, territory and national legislative frameworks, and to manage their prescribing practices within the laws and clinical and professional standards.

Practitioners who are unaware of their legal obligations risk being the subject of legal prosecution and/or disciplinary action by the medical board.

GPs need to be aware of their obligations regarding the impact of medication on the patient’s ability to safely perform usual activities such as driving (eg Jet’s Law in Queensland ).

Medical defence organisations provide support and information on prescribing drugs of dependence. For more information, visit:

Evidence-based medicine

Doctors should use evidence-based interventions where they are available.

Occasionally, doctors prescribe drugs of dependence to address perceived patient expectations, but without necessarily improving health and potentially resulting in harm.

Unfortunately, there are few quality measures for accountable prescribing.45 Protocols may be useful to ensure consistent provision of good practice. The practice team should work within a clinical governance framework and be prepared to justify their clinical decisions, particularly when operating outside guidelines. Doctors should keep comprehensive notes to support their decisions and monitor the effectiveness of their care using clinical audit.

Skills and knowledge

GPs are expected to update their knowledge and skills according to emerging evidence and developments in professional practice. It is each practitioner’s responsibility to ensure competency in the areas they choose to manage. Practitioners should also be aware of their clinical limitations.47

Doctors who are untrained48 or become ‘dated’ in their clinical competencies can be at higher risk for inappropriate prescribing.49

Numerous educational interventions have been conducted to improve prescribing competency.50 The World Health Organization’s (WHO) Guide to good prescribing51 has the largest body of evidence to support its use in a wide variety of settings.50,52

Doctors prescribing drugs of dependence should review their pharmacology, including pharmacokinetic and pharmacodynamic properties, drug–drug interactions and signs of intoxication and withdrawal. They should also be aware of the epidemiology of abuse and appropriate treatment indications and contraindications, and they should be able to perform basic alcohol and drug addiction screening assessments.53

Community pharmacists may be a valuable resource.54

Universal precautions

Adoption of a universal precautions approach (used in pain medicine) may improve patient care and minimise the risk of harm and medico-legal issues. The following universal precautions are a guide to the proper evaluation and management of patients, and are applicable to all drugs of dependence:55

  • Make a diagnosis with appropriate differential diagnoses.
  • Undertake a psychosocial assessment that includes risk of addictive disorders.
  • Use informed consent.
  • Use treatment agreements.
  • Undertake a pre- and post-intervention assessment that includes pain score and level of function.
  • Commence a trial of appropriate opioid therapy with an appropriate combination of adjunctive medications.
  • Reassess pain score and level of function.
  • Routinely assess the five As of pain medicine (analgesia, activity, adverse events, aberrant behaviour, affect).
  • Periodically review the diagnosis and comorbid conditions, including addictive disorders.
  • Carefully document initial assessment and each follow-up.

Prescription writing

GPs should use prescription-writing techniques to minimise misuse and abuse.

When writing prescriptions for drugs of dependence, GPs must:53

  • prescribe the appropriate amount to carry through to the next appointment
  • write out the number dispensed in letters and numerals (ie 14 and fourteen)
  • draw a large ‘Z’ at the bottom of the prescription so that further items cannot be added (if using paper prescription stationery).

Prescribers can decrease the risk of misuse by reducing access and temptation to overuse medication through much more frequent dispensing of smaller quantities of medications. This can range from weekly, twice weekly to daily (supervised) dispensing. This is aided by a one-practice and, preferably, one-GP approach, and the dispensing of medication through one pharmacy.

The ‘prescription traps’

The following is a compilation of prescription issues that have been noted in coroners’ proceedings. GPs are advised to consider these in reviewing their own prescribing habits.

  • Patients requesting private scripts for drugs of dependence.
  • Patients presenting with out-dated doctor’s letter requesting medication.
  • Excessive prescribing without proper assessment of potential psychiatric conditions.
  • Excessive prescribing without proper assessment of pain management options, including specialist referral.
  • Prescribing contrary to statutory guidelines or regulations.
  • Prescribing dangerous (high-risk) medication to unknown patients, particularly opioids and benzodiazepines.
  • Prescribing benzodiazepines as a first-line treatment for psychiatric disorders.
  • The inappropriate use of benzodiazepines in pain management.
  • The inappropriate use of opioids in pain management, particularly chronic non-malignant pain.
  • The inappropriate combined use of benzodiazepines and opioids in pain management.
  • The use of pethidine in pain management (particularly for the treatment of migraines).
  • The use of injectable medication, particularly opioids, by GPs for pain treatment.
  • Prescription of medications with potentially dangerous interactions, particularly, tramadol and antidepressant medication (risk of serotonin syndrome).
  • The use of quetiapine to treat insomnia and anxiety.

Working collaboratively

Doctors need to work with a range of other professionals and may work as part of a wider organisation or in a multidisciplinary team. It is usually good practice to ensure that clinical practices are standardised through local area policies and protocols. Depending on the setting and nature of the organisation (eg community drug treatment, primary care–led drug treatment service, hospital-based drug treatment service), doctors should be aware of accepted best practice protocols and work in accordance with these.

Patients who are at higher risk for dependency or have more complex issues need to be jointly managed between primary care and specialised drug and alcohol/addiction services, and require the input of mental health and/or pain specialists as required.

Managing issues between multiple providers

Circumstances occasionally arise when GPs feel uncomfortable about continuing care from other practitioners. GPs are under no obligation to continue another prescriber’s action if they deem this to be unsafe, inappropriate or impractical, such as:

  • drugs being prescribed off label, particularly drugs used for mental illness
  • disagreement between the GP and specialist about whether a drug of dependence is warranted
  • excessive prescribing that the GP is uncomfortable continuing.

There needs to be provision within the system for case conference and collaborative discussion of evidence-based treatment where all views are taken into consideration. When a GP does not feel happy to provide a prescription, they should not feel pressured to do so. The ideal situation is to have an independent drug and alcohol specialist review the case. Alternatively, referral back to the original provider for scripts may be warranted.

If taking over the care of an inherited patient, the GP should ask the following questions:56

  • Does this patient have a clear chronic pain disorder and/or mental illness diagnosis?
  • Is there justification for the drugs that have been prescribed?
  • Are the prescribed amounts appropriate?
  • If a patient is displaying drug-seeking behaviours, is this a sign of under-treated pain, addiction, or involvement in abuse or diversion of S8 opioids?

Getting support

Prescribing decisions around drugs of dependence can be difficult and new evidence is constantly emerging. GPs need to keep up to date with best prescribing practices. Formal and informal professional support (eg mentoring, clinical review, education, joining professional networks, using decision support tools) is important for all GPs and may be particularly relevant for GPs working in isolation.

There is some evidence that sole practitioners who are not affiliated with any professional college (ie not actively engaged in ongoing professional development programs) and treating opioid-dependent patients over a long period are at risk of inappropriate prescribing.5 Inappropriate prescribing can be the result of not taking a drug history, not conducting a physical examination and not asking if patients have had these drugs prescribed for them before, and, if so, when. Quality improvement activities such as continuing audit, clinical review and educative support may help reduce inappropriate prescribing.57–59

Deciding when to seek advice or consider referral to a psychiatrist or pain/addiction specialist

The ongoing treatment of pain, addiction and mental illness comorbidities is a complex undertaking. Initial referral may be needed to obtain a comprehensive evaluation, or to clarify the optimal therapeutic strategies.

Referral is typically considered for patients who are at higher risk, who have more complex needs or in patients at risk of adverse events. For example, patients who:56

  • are relatively young (eg <35 years old)
  • have a comorbid psychiatric or psychological disorder
  • have previous or current opioid, or SUDs
  • have indeterminate pathology.

Once an optimal regimen and monitoring approach has been implemented, referral may be warranted for the following reasons:56

  • unexpected drug dose escalation
  • ceiling drug dosages reached
  • suspected abuse or misuse
  • risk category change
  • high levels of patient distress
  • unusual opioid requirements or suspicions of drug diversion
  • poorly controlled comorbid psychiatric or psychological disorder.

Deciding when to refer a patient for hospital admission (through emergency departments)

Patients may need referral to hospital if they are at risk to themselves, pose risks to others or at risk by others.

Table 2. Identifying patient risk

Table 2

Identifying patient risk

Record keeping

GPs must maintain adequate, accurate and timely records regarding pain assessment, treatment plan, informed consent, ongoing assessment and consultation of the patient.

‘Adequate records’ refers to legible records containing, at a minimum, sufficient information to identify the patient, support the diagnosis and justify the treatment; adequate documentation of the results; advice and risks provided to the patient; and sufficient information for another practitioner to assume continuity of the patient’s care at any point in the treatment.

GPs also need to document the process of shared decision making and what information is shared.

All drugs of dependence have the potential to be misused. Even when used as prescribed, they can cause harms. Before prescribing or continuing to prescribe them to any patient, the patient should be assessed and their needs and risks determined.

More detailed information will be available in the RACGP’s separate guidelines on benzodiazepines and opioids.

General assessment

Drug-seeking patients can often provide well-developed clinical histories which may seem very ‘real’. There is often a strong aim to work on the desire of doctors to minimise the distress of patients. Rather than being aggressive, many will be very pleasant with a credible story.

In addition, not all drug-seeking patients are faking symptoms. They may have a legitimate complaint and, over time, have become dependent or tolerant and require larger doses of medication to function in their daily life.

In patient presentations where drugs of dependence may be indicated, a full assessment includes:

  • a full history, including the use of alcohol and other drugs (including over-the-counter medications medicines containing codeine combined with ibuprofen or paracetamol), psychiatric comorbidity, family history and family/social situation – this also helps identify people at higher risk of developing problems
  • adequate physical examination (including looking for signs of intoxication or withdrawal or intravenous drug use)
  • problem/diagnosis list
  • management plan
  • communication with other providers (eg methadone prescriber, pharmacist, other GP)
  • prescription shopper communication (refer to Section 3.8  of the PDF version for more information)
  • consider urine drug screening/testing (refer to Appendix H of the PDF version).

This should enable a diagnosis of a patient with genuine medical need and no dependence, a patient with genuine medical need and dependence,* or a patient that may be looking for drugs of dependence for non-medical use.

Once a full assessment, including assessment of dependence (refer to Assessment of substance use disorder), has been carried out, a care or treatment plan can be established.

*This may also be pseudo-addiction where a patient with undiagnosed and/or inadequately treated painful condition adopts drug-seeking behaviour in an attempt to achieve relief.60

Assessment of substance use disorder

Patients who have current or previous substance-related problems have a greater risk of harm and ongoing problematic use, therefore specialist support and advice should be considered as part of ongoing management.

The new Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria combine the old DSM-IV categories of substance abuse and substance dependence into a single condition of SUD, which is measured on a continuum from mild to severe.61 This diagnosis can be applied across all drugs of dependence (as well as drugs such as nicotine and alcohol) and should reduce confusion associated with the terms dependence, addiction and abuse (which have been inconsistently and often incorrectly used to describe points on a spectrum of disordered use).

The essential feature of SUD is a cluster of cognitive, behavioural and physiological symptoms indicating the individual continues using the substance despite significant substance-related problems.61

Diagnosing SUD requires the presence of at least two of 11 criteria, across four categories: impaired control, social impairment, risky use and pharmacology. Based on the total number of criteria the patient has, the SUD can be classified as mild (2–3 symptoms), moderate (4–5 symptoms) or severe (6 or more symptoms). It is hoped these severity classifiers may potentially help clarify treatment options (Table 3).

Although the term SUD is a helpful addition, the term addiction will necessarily be used when discussing any drugs of dependence.

Table 3. DSM-5 criteria for diagnosing an SUD

Table 3

DSM-5 criteria for diagnosing an SUD

Prescribing drugs of dependence should be seen as an adjunct to care, and not regarded as the primary treatment regimen.

For many of the conditions which drugs of dependence are used, non-drug interventions are often more effective and have sustained results.62–67 Where there is good evidence for non-drug interventions, GPs should consider these as first-line therapy. GPs need to be aware of the evidence for allied health treatments and be able to offer these (in-house or through referral) to patients when they need them.

There is substantial evidence that anxiety, depression, sleep and chronic pain problems, including headache and migraine, can be effectively treated with cognitive behaviour therapy (CBT) and other psychological approaches.62 Further, there is evidence that in many cases, psychological therapies are at least equivalent and sometimes superior to the use of medicines to address these issues.62–67

In cases where the use of medicines is indicated, concurrent psychological therapy is typically superior to either therapy alone.68

Refer to individual drug guides for further information.

  1. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009;39(10):676–81.
  2. United Nations Office on Drugs and Crime. World Drug Report 2014. New York: United Nations; 2014.
  3. Dobbin MD. Pharmaceutical drug misuse in Australia. Australian Prescriber 2014;37(3):79–81.
  4. National Drug Strategy. National pharmaceutical drug misuse framework for action 2012–2015 – A matter of balance. Canberra: NDS, 2011. [Accessed 22 May 2015].
  5. Nicholas R, Lee N, Roche A. Pharmaceutical Drug Misuse in Australia: Complex Problems, Balanced Responses. Adelaide: National Centre for Education and Training on Addiction (NCETA), Flinders University; 2011.
  6. Office of National Drug Control Policy (ONDCP). Epidemic: Responding to America’s Prescription Drug Abuse Crisis. Washington DC: Executive Office of the President of the United States; 2011.
  7. College of Physicians and Surgeons of Ontario. Avoiding Abuse, Achieving a Balance: Tackling the Opioid Public Health Crisis. Toronto: CPSO; 2010.
  8. Medicare Australia Statistics. Pharmaceutical Benefits Schedule Item Reports.
  9. [Accessed January 2014].
  10. Nicholas R, Lee N, Roche A. Pharmaceutical Drug Misuse in Australia: Complex Problems, Balanced Responses. Adelaide: National Centre for Education and Training on Addiction (NCETA); 2011.
  11. National Drug Strategy Household Survey Canberra: AIHW; 2014. [press release].
  12. Fitzroy Legal Service. Harms caused by drugs. Melbourne: Fitzroy Legal Services; 2014. [Accessed January 2014].
  13. Harris KM, Edlund MJ. Self-medication of mental health problems: new evidence from a national survey. Health Serv Res 2005;40(1):117–34.
  14. Nielsen S, Bruno R, Lintzeris N, Fischer J, Carruthers S, Stoove M. Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia? Drug Alcohol Rev 2011;30(3):291–9.
  15. Nielsen S, Bruno R, Degenhardt L, et al. The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids.Med J Aust 2013;199(10):696–99.
  16. Healy J, Braithwaite J. Designing safer health care through responsive regulation. Med J Aust 2006;184(10 Suppl):S56–9.
  17. Haines F. Regulatory failures and regulatory solutions: a characteristic analysis of meta-regulation. Proceedings, Annual Meeting. Baltimore,MD: Law and Society Association; 2006.
  18. Parker C. The open corporation: effective self-regulation and democracy. Cambridge: Cambridge University Press; 2002.
  19. Scally G, Donaldson LJ. The NHS’s 50 anniversary. Clinical governance and the drive for quality improvement in the new NHS in England. BMJ 1998;317(7150):61–5.
  20. Healthdirect Australia. Clinical Governance Framework. Sydney: Healthdirect Australia; 2013.
  21. The Royal Australian College of General Practitioners. Standards for general practices, 4th edition. Melbourne: RACGP; 2013.
  22. Harris S, Taylor S, Agency NT. Clinical governance in drug treatment: A good practice guide for providers and commissioners. London: NTA; 2009.
  23. MDA National. Things to Think About Before You… Prescribe Schedule 8 Drugs MDA National. [press release].
  24. Cran A. Misuse of opioid drugs. Defence Update: A quarterly publication for MDA National Members [Internet]. Sydney: MDA National; 2013. [Accessed January 2014].
  25. Prescription Benefits Scheme. 2. Prescribing Medicines – Information for PBS Prescribers Canberra: Department of Health. January 2014].
  26. Medicare. Practitioner Review Program Canberra: Australian Government; 2013 [updated 1 August 2013, January 15, 2014]. [Accessed January 2014].
  27. The Royal Australian College of General Practitioners. What is General Practice? Melbourne: RACGP; 2012. [Accessed September 2013].
  28. Keckley PH, Hoffmann M, Underwood HR. Medical Home 2.0: The Present, the future. Washington, DC: Deloitte Centre for Health Solutions; 2010.
  29. American Academy of Family Physicians (AAFP) AAoPA, American College of Physicians (ACP), American Osteopathic Association (AOA). Joint Principles of the Patient-Centered Medical Home. Washington, DC: Patient Centred Primary Care; 2007.
  30. Saultz JW, Albedaiwi W. Interpersonal continuity of care and patient satisfaction: a critical review. Ann Fam Med 2004;2(5):445–51.
  31. Grumbach K, Grundy P. Outcomes of implementing patient centred medical home interventions: A review of the evidence from prospective studies in the United States Washington DC: Patient-Centred Primary Care Collaborative; 2010.
  32. Geisinger Health System. Presentation at White House Roundtable on Advanced Models of Primary Care: August 10, 2009. Washington DC; 2009.
  33. Steiner BD, Denham AC, Ashkin E, Newton WP, Wroth T, Dobson LA, Jr. Community care of North Carolina: improving care through community health networks. Ann Fam Med 2008;6(4):361–67.
  34. Scholle SH. Developing and testing measures of patient centred care. New York: The Commonwealth Fund; 2006.
  35. Beal A. Closing the divide: how medical homes promote equity in Health care. New York: The Commonwealth Fund; 2007.
  36. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011;(10):CD004147.
  37. Heit HA, Lipman AG. Pain: Substance Abuse Issue in the Treatment of Pain. In: Moore RJ, editor. Biobehavioral Approaches to Pain. New York: Springer Science+Business Media, LLC; 2009. p. 363–81.
  38. National Drug Stategy amd National Mental Health Strategy. National Comorbidity Project. Canberra: of Health and Aged Care; 2001.
  39. Australian Commission on Safety and Quality in Health Care. Safety and Quality Improvement Guide Standard 6: Clinical Handover (October 2012). Sydney: ACSQHC; 2012.
  40. Medicare Australia. Prescription Shopping Program 2014. [Accessed January 2014].
  41. Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend 2005;78(1):49–56. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract 2011;61(590):e573–78.
  42. Department of Health (England) and the devolved administrations. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Govenment and Northern Ireland Executive; 2007.
  43. Travaglia J, Debono D. Clinical audit: a comprehensive review of the literature. Sydney: Centre for Clinical Governance Research in Health, Faculty of Medicine, University of New South Wales; 2009.
  44. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012;6:CD000259.
  45. Morden NE, Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med 2013;369(4):299–302.
  46. Walter J. Prescribing for self and family: one national system, eight different rules. Sydney: MDA National; 2012. [Accessed January 2014].
  47. General Medical Council. Good practice in prescribing and managing medicines and devices. London: GMC; 2013.
  48. Aronson JK, Henderson G, Webb DJ, Rawlins MD. A prescription for better prescribing. BMJ 2006;333(7566):459–60.
  49. Wolfert MZ, Gilson AM, Dahl JL, Cleary JF. Opioid analgesics for pain control: Wisconsin physicians’ knowledge, beliefs, attitudes and prescribing practices. Pain Med 2010;11(3):425–34.
  50. Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve prescribing competency: a systematic review. BMJ Open 2013;3(8):e003291.
  51. de Vries TPGM, Henning RH, Hogerzeil HV, Fresle DA. Guide to Good Prescribing: A practical manual. Geneva: World Health Organization Action Programme on Essential Drugs; 1994.
  52. Ross S, Loke YK. Do educational interventions improve prescribing by medical students and junior doctors? A systematic review. Br J Clin Pharmacol 2009;67(6):662–70.
  53. Longo LP, Parran T, Jr., Johnson B, Kinsey W. Addiction: part II. Identification and management of the drug-seeking patient. Am Fam Physician 2000;61(8):2401–8.
  54. Majumdar SR, Soumerai SB. Why most interventions to improve physician prescribing do not seem to work. CMAJ 2003;169(1):30–1.
  55. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107–12.
  56. Drugs and Alcohol Services South Australia. Opioid prescription in chronic pain conditions. Adelaide: DAAS SA, the Flinders Medical Centre Pain Management Unit and the Royal Adelaide Hospital Pain Management Unit; 2008.
  57. Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. Am J Manag Care 2013;19(8):648–65.
  58. Fries Taylor E, Genevro J, Peikes D, Geonnotti K, Wang W, Meyers D. Buiding Quality Improvement Capacity in Primary Care: Supports and Resources. Decisiomaker Brief: Primary Care Quality Improvement No. 2. Rockville: AHRQ; 2013.
  59. Elliott RA, Woodward MC, Oborne CA. Improving benzodiazepine prescribing for elderly hospital inpatients using audit and multidisciplinary feedback. Intern Med J 2001;31(9):529–35.
  60. Clubb B. The drug seeking patient. Brisbane: Professor Tess Cramond Multidisciplinary Pain Clinic, Royal Brisbane and Women’s Hospital; 2009.
  61. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. Arlington: American Psychiatric Publishing; 2013.
  62. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26(1):17–31.
  63. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003;(1):CD003161.
  64. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract 2012;13:40.
  65. Kierlin L. Sleeping without a pill: non pharmacological treatments for insomnia. Journal of Pscychiatric Practice 2008;14(6):403–7.
  66. Hasora P, Kessmann J. Nonpharmacological management of chronic insomnia. Am Fam Physician 2009;79(2):125–30.
  67. Gunter RW, Whittal ML. Dissemination of cognitive-behavioral treatments for anxiety disorders: Overcoming barriers and improving patient access. Clin Psychol Rev 2010;30(2):194–202.
  68. Morin CM, Vallieres A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009;301(19):2005–15.
  69. Patient Safety and Quality Improvement Service. Guide to Informed Decision-making in Healthcare. Brisbane: Queensland Health; 2012.
  70. World Health Organization. Lexicon of alcohol and drug terms published by the World Health Organization Geneva: WHO; 2014.
  71. O’Regan R. Drug Seeking Behaviour: Identifying and dealing with the issues. Perth: North Metro Community Drug Service; 2012.
  72. The Royal Australasian College of Physicians. Precription Opioid Policy: Improving management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. Sydney: RACP; 2009.
  73. Therapeutic Goods Administration. Scheduling basics Canberra: Department of Health; 2011. [Accessed January 2014].
  74. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152(2):85–92.
  75. Agency Medical Directors’ Group. Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An educational aid to improve care and safety with opioid therapy. Washington: AMDG; 2010.
  76. Rossi Se. Australian Medicines Handbook 2011. Adelaide: Australian Medicines Handbook Pty Ltd; 2011.
  77. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2013 [Accessed December 2013].
  78. WA Cancer and Palliative Care Network. Opioid Coversion Chart. Perth: Department of Health and Ageing; 2010. [Accessed July 2014].
  79. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Hamilton: McMaster University; 2010.
  80. Robinson G. Prescription drug misuse: How to identify and manage drug seekers. BPJ 2008;(16):18–23.
  81. Friese G, Wojciehoski RF, Friese A. Drug seekers: do you recognize the signs? Emerg Med Serv 2005;34(10):64–7, 88–9.
  82. Rull G. Assessment of Drug Dependence. Leeds: Egton Medical Information Systems; 2011.
  83. Ford C, Halliday K, Lawson E, Brown E. Guidance for the use of substitute prescribing in the treatment of opioid prescribing in the treatment of opioid dependence in primary care. London: RCGP; 2011.
  84. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc 2008;83(1):66–76.
  85. National Opioid Use Guideline Group. Canadian Guideline for Safe and Effective Use of Opioid for Chronic Non-Cancer Pain: NOUGG; 2010.
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log